Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Sotac Pharmaceuticals's Marketable Securities for the quarter that ended in Mar. 2026 was ₹0.0 Mil.
Sotac Pharmaceuticals's annual Marketable Securities
increased
from Mar. 2024 (₹0.0 Mil) to Mar. 2025 (₹2.3 Mil) but then
declined
from Mar. 2025 (₹2.3 Mil) to Mar. 2026 (₹0.0 Mil).
Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.
Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".
Sotac Pharmaceuticals Marketable Securities Related Terms
Sotac Pharmaceuticals Marketable Securities Historical Data
* Premium members only.
The historical data trend for Sotac Pharmaceuticals's Marketable Securities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Marketable Securities of ₹0.0 Mil mean?
Sotac Pharmaceuticals (NSE:SOTAC) has a Marketable Securities of ₹0.0 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Sotac Pharmaceuticals and its competitors.
Is Sotac Pharmaceuticals' Marketable Securities too high?
Sotac Pharmaceuticals' current Marketable Securities is ₹0.0 Mil. Overall, Sotac Pharmaceuticals has a GF Score™ of 53/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sotac Pharmaceuticals' Marketable Securities compare to ZTS?
Sotac Pharmaceuticals' Marketable Securities of ₹0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Drug Manufacturers company?
A good Marketable Securities depends on the Drug Manufacturers industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Sotac Pharmaceuticals and its competitors. Sotac Pharmaceuticals's current Marketable Securities is ₹0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sotac Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Sotac Pharmaceuticals (NSE:SOTAC) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹141.76, compared to a current price of ₹91.95 — trading 35.1% below its estimated fair value. The current Marketable Securities is ₹0.0 Mil. Sotac Pharmaceuticals' overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Sotac Pharmaceuticals (NSE:SOTAC), the current Marketable Securities is ₹0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sotac Pharmaceuticals (NSE:SOTAC) Overvalued in 2026?
Based on GuruFocus' analysis, Sotac Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹91.95 is trading 35.1% below its estimated GF Value™ of ₹141.76.
GuruFocus considers Sotac Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for NSE:SOTAC:
Marketable Securities: ₹0.0 Mil
GF Value™: ₹141.76 vs. price of ₹91.95 (35.1% below fair value)
No single metric tells the full story. See the NSE:SOTAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sotac Pharmaceuticals Ltd operates chiefly in pharmaceutical manufacturing, serving a broad range of therapeutic segments including anti-diabetic, anti-psychotic, vitamins and minerals, anti-cold, anti-allergic, derma products, antacids, anti-ulcerants, cardiac, analgesic, anti-bacterial, anti-fungal, and more. The company manufactures tablets, capsules, syrups, and external preparations under contract manufacturing and loan licensing agreements, for domestic and international markets. Its clients include notable pharmaceutical marketers such as Cadila Pharma and Viatris. Revenue is distributed between domestic pharmaceutical product sales and international exports, supporting scalable growth across geographies.
53GF Score
Get the complete analysis for NSE:SOTAC
Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SOTAC has been successfully added to your 
